Adam D Cohen, MD

faculty photo
Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine

Contact information
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-175
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: 215-615-5853
Fax: 215-615-5887
Harvard University, 1994.
University of Pennsylvania, 1999.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Clinical Expertise

Multiple Myeloma
POEMS syndrome
Monoclonal gammopathies
Waldenstrom's Macroglobulinemia

Description of Research Expertise

Cancer immunotherapy
Cellular therapy
Phase I trials
CAR T cells

Selected Publications

Ailawadhi S, Sexton R, Lentzsch S, Abidi MH, Voorhees PM, Cohen AD, Rohren E, Heitner S, Kelly K, Mackler NJ, Baer DM, Hoering A, Durie BG, Orlowski RZ: Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma. Clin Cancer Res Apr 16 2020 Notes: doi: 10.1158/1078-0432.CCR-19-1997. Online ahead of print.

AD Cohen, N Raje, J Fowler, K Mezzi, EC Sctoo, MV Dhodapkar: How to train your T cells: overcoming immune dysfunction in multiple myeloma. Clinical Cancer Research 26(7): 1541-1554, Apr 1 2020.

Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah A-O, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facun T, Hulin C, Kortum M, Rodriguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Pointek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD: Belantamab mafotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm randomised, open label, phase 2 study. Lancet Oncology 21(2): 207-221, Feb 2020.

Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang WT, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker K, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH: CRISPR-engineered T cells in patients with refractory cancer. Science 367(6481): eaba7365, Feb 28 2020.

Cohen AD: Myeloma: next-generation immunotherapy. Hematology. American Society of Hematology Education Program. 2019(1): 266-272, Dec 2019.

Costello CL, Gregory TK, Ali SA, Berdeja JG, Patel KK, Shah ND, Ostertag E, Martin C, Ghoddusi M, Shedlock DJ, Spear MA, Orlowski RZ, Cohen AD: Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME). Blood, ASH Annual Meeting, Orlando, FL 134(Supplement 1): 3184, Dec 2019.

Weng M, Pruteanu I, Cohen AD, Garfall AL, Tian L, Lacey SF, Fraietta J, Brogdon J, Davis M, Gonzalez VE, Levine BL, Siegel DL, Milone MC, Stadtmauer EA, June CH, Melenhorst JJ.: Response to Anti-BCMA CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma Blood, ASH Annual Meeting, Orlando, FL 134(Supplement_1): 1909, Dec 2019.

Gertz MA, Cohen AD, Comenzo RL, Dumond C, Kastritis E, Landau HJ, Libby EN, Liedtke M, Merlini G, Sanchorawala V, Schonland SO, Wechalekar AD, Zonder JA, Kinney G: Results of the Phase 3 VITAL Study of NEOD001 (Birtamimab) Plus Standard of Care in Patients with Light Chain (AL) Amyloidosis Suggest Survival Benefit for Mayo Stage IV Patients. Blood, ASH Annual Meeting, Orlando, FL 134(Supplement 1), Dec 2019.

Wang M, Pruteanu I, Cohen AD, Garfall AL, Milone MC, Tian L, Gonzalez VE, Gill S, Frey NV, Barrett DM, Ruella M, Lacey SF, Svoboda J, Chong EA, Fraietta JA, Davis M, Nasta SD, Levine BL, Siegel DL, Maude SL, Schuster SJ, Stadtmauer EA, Grupp S, Porter DL, June CH, Melenhorst JJ.: Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors. Blood, ASH Annual Meeting, Orlando, FL 134(Supplement 1): 622, Dec 2019.

Garfall AL, Cohen AD, Lacey SF, Tian L, Hwang W-T, Vogl DT, Waxman A, Lancaster E, Nelson AM, Ferthio R, Fesnak A, Lamontagne A, Brenna A, Guilliams J, Gladney WL, Melenhorst JJ, Young RM, Siegel DL, Levine BL, Brogdon J, Isaacs RE, June CH, Milone MC, Stadtmauer EA: Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma. Blood, ASH Annual Meeting, Orlando, FL 134(Supplmement 1): 1863, Dec 2019.

back to top
Last updated: 05/28/2020
The Trustees of the University of Pennsylvania